LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Listă Acțiuni・Biogen Inc

Biogen Inc

Închisă

Sector Sănătate

200.08 -0.66

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

199.46

Maxim

200.85

Indicatori cheie
By Trading Economics
Venit	190M 584M
Vânzări	180M 2.5B
P/E Medie Sector	28.98 103.001
EPS	5.28
Marjă de profit	23.628
Angajați	7,570
EBITDA	237M 919M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+37 upside

Statistici piață
By TradingEconomics
Capitalizare de piață	122M 30B
Deschiderea anterioară	200.74
Închiderea anterioară	200.08

Sentimentul știrilor

By Acuity

34%

66%

64 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

198.19 / 204.86 Suport & Rezistență

Biogen Inc Grafic

Știri relevante

6 sept. 2024, 11:00 UTC

Top știri

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29 mai 2024, 15:56 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

4 oct. 2023, 17:55 UTC

Achiziții, Fuziuni, Preluări

Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment? -- IBD

Comparație

Modificare preț

Biogen Inc Așteptări

Obiectiv de preț

By TipRanks

37% sus

Prognoză pe 12 luni

Medie 275.11 USD 37%

Maxim 342 USD

Minim 190 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBiogen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 19 analiști care au acordat evaluări ale acțiunilor Biogen Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

198.19 / 204.86Suport & Rezistență

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

64 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.